Capricor to present 24-month HOPE-3 data on deramiocel in Duchenne muscular dystrophy at World Muscle Society congress
CAPR•Capricor to present 24-month HOPE-3 data at WMS 2026
Capricor to present 24-month HOPE-3 data on deramiocel in Duchenne muscular dystrophy at World Muscle Society congress
- Capricor flagged new 24-month HOPE-3 results for deramiocel in advanced Duchenne muscular dystrophy, slated for late-breaking release at WMS 2026.
- The data are positioned to support both muscle function and cardiac benefit, extending previously disclosed 12-month findings.
- Analyses include delayed-start and natural-history comparisons, submitted in a major amendment to the deramiocel BLA.
- WMS 2026 runs Sept. 29 to Oct. 3 in Hiroshima; an oral clinical-trial update is scheduled for Oct. 3.
- The FDA PDUFA target action date for the deramiocel BLA is Nov. 22, 2026.
